Teva (TEVA) officer Mark Sabag sells 62,102 shares in open-market trade

Rhea-AI Filing Summary

Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.

Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.

Insights

Equity ownership analyst

Officer executes a routine open-market share sale, retaining a substantial remaining position.

The filing shows Teva officer Mark Sabag completed an open-market sale of 62,102 Ordinary Shares at a weighted average of $30.141 on March 17, 2026. Pricing was within a narrow band of $30.115 to $30.215, suggesting normal market execution.

After the sale, Sabag still holds 224,940 Ordinary Shares, indicating he retains a significant stake. There are no derivative positions listed and no reference to a Rule 10b5-1 trading plan in the provided footnotes, so this appears as a straightforward discretionary sale based on the available information.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/17/2026		S		62,102	D	$30.141(2)	224,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.115 to $30.215, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Teva (TEVA) officer Mark Sabag report in this Form 4?

He reported selling 62,102 Teva Ordinary Shares. The transaction was an open-market sale at a weighted average price of $30.141 per share on March 17, 2026, and is disclosed as a routine insider trade.

At what price did Mark Sabag sell Teva (TEVA) shares?

The weighted average sale price was $30.141 per share. Footnotes explain the shares were sold in multiple trades, with individual prices ranging from $30.115 to $30.215, all executed on March 17, 2026, in open-market transactions.

How many Teva (TEVA) shares does Mark Sabag hold after the sale?

He directly holds 224,940 Ordinary Shares after the sale. This post-transaction balance shows that, despite disposing of 62,102 shares, he maintains a substantial continuing equity stake in Teva Pharmaceutical Industries.

What type of transaction did Teva (TEVA) report for Mark Sabag?

The filing reports an open-market sale of Ordinary Shares. The transaction code is “S,” described as a sale in open market or private transaction, with 62,102 shares sold and no accompanying derivative exercises or tax-withholding entries.

Are Teva (TEVA) Ordinary Shares linked to American Depositary Shares in this Form 4?

Yes, each Ordinary Share may be represented by one ADS. A footnote clarifies that Teva’s Ordinary Shares can be held as American Depositary Shares, with each ADS currently corresponding to one Ordinary Share on a one-for-one basis.